Addition of platinum salts to neoadjuvant chemotherapy in triple-negative breast cancer: a new standard of care?
Mené sur 634 patientes atteintes d'un cancer du sein triple négatif, cet essai de phase III évalue l'efficacité, du point de vue du taux de réponse pathologique complète, et la toxicité de l'ajout du véliparib, un inihibiteur de PARP, au carboplatine et à une chimiothérapie néoadjuvante standard à base de paclitaxel
The St Gallen Consensus Conference panel strongly endorsed the preference for neoadjuvant therapy in stage II and III triple-negative breast cancer.1 In The Lancet Oncology, Sibylle Loibl and colleagues report the results of the randomised, double-blind, phase 3, BrighTNess trial.2 The study assessed the addition of the poly(ADP-ribose) polymerase (PARP) inhibitor veliparib plus carboplatin, or carboplatin alone, to a standard neoadjuvant chemotherapy regimen (weekly paclitaxel followed by doxorubicin and cyclophosphamide) in patients with triple-negative breast cancer, and showed that the proportion of patients who achieved a pathological complete response significantly improved in the veliparib plus carboplatin plus paclitaxel group compared with the paclitaxel-based chemotherapy alone group (168 [53%] of 316 patients vs 49 [31%] of 158 patients, p=0·001), confirming the results of the previous, phase 2, I-SPY 2 trial.
The Lancet Oncology , commentaire, 2017